MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative product candidates. The company aims to address unmet medical needs through its proprietary therapies, which are currently in various stages of preclinical and clinical development. Their business model relies on securing substantial financing to support ongoing research and development efforts.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | Not provided | Not provided | Not provided |
| Adjusted Net Loss | -$77.6M | -$55.7M | Not provided |
The company operates in the biopharmaceutical market and competes with established players like Amgen and Gilead Sciences. The industry is characterized by lengthy and expensive drug development processes with significant regulatory hurdles.
MapLight Therapeutics plans to use the proceeds from the IPO to fund research and development activities, as well as for general corporate purposes.
No broker information available yet
Check back later for updates
Reported by users or publicly disclosed. Information is for reference only.